HRP20230947T1 - Postupci i kompozicije za imunološku zaštitu od izvancrijevne patogene e. coli - Google Patents
Postupci i kompozicije za imunološku zaštitu od izvancrijevne patogene e. coli Download PDFInfo
- Publication number
- HRP20230947T1 HRP20230947T1 HRP20230947TT HRP20230947T HRP20230947T1 HR P20230947 T1 HRP20230947 T1 HR P20230947T1 HR P20230947T T HRP20230947T T HR P20230947TT HR P20230947 T HRP20230947 T HR P20230947T HR P20230947 T1 HRP20230947 T1 HR P20230947T1
- Authority
- HR
- Croatia
- Prior art keywords
- coli
- antigen
- polysaccharide
- polysaccharides
- formula
- Prior art date
Links
- 241000588724 Escherichia coli Species 0.000 title claims 45
- 239000000203 mixture Substances 0.000 title claims 13
- 230000001717 pathogenic effect Effects 0.000 title claims 4
- 239000000427 antigen Substances 0.000 claims 46
- 102000036639 antigens Human genes 0.000 claims 46
- 108091007433 antigens Proteins 0.000 claims 46
- 229920001282 polysaccharide Polymers 0.000 claims 45
- 239000005017 polysaccharide Substances 0.000 claims 45
- 150000004676 glycans Chemical class 0.000 claims 40
- 102000014914 Carrier Proteins Human genes 0.000 claims 5
- 108010078791 Carrier Proteins Proteins 0.000 claims 5
- -1 O1A polysaccharide Chemical class 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 4
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 206010056519 Abdominal infection Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010058780 Meningitis neonatal Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010058674 Pelvic Infection Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 201000001177 Pyomyositis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010062255 Soft tissue infection Diseases 0.000 claims 1
- 208000031650 Surgical Wound Infection Diseases 0.000 claims 1
- 206010048038 Wound infection Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562209091P | 2015-08-24 | 2015-08-24 | |
| US201562210655P | 2015-08-27 | 2015-08-27 | |
| EP16760616.9A EP3341016B9 (en) | 2015-08-24 | 2016-08-24 | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli |
| PCT/US2016/048278 WO2017035181A1 (en) | 2015-08-24 | 2016-08-24 | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230947T1 true HRP20230947T1 (hr) | 2023-11-24 |
Family
ID=56855827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230947TT HRP20230947T1 (hr) | 2015-08-24 | 2016-08-24 | Postupci i kompozicije za imunološku zaštitu od izvancrijevne patogene e. coli |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10583185B2 (enExample) |
| EP (2) | EP4245320A3 (enExample) |
| JP (1) | JP6872532B2 (enExample) |
| KR (1) | KR102735147B1 (enExample) |
| CN (1) | CN108430500B (enExample) |
| AU (1) | AU2016312422B2 (enExample) |
| BR (1) | BR112018003469A2 (enExample) |
| EA (1) | EA037500B1 (enExample) |
| ES (1) | ES2951408T3 (enExample) |
| HR (1) | HRP20230947T1 (enExample) |
| HU (1) | HUE063961T2 (enExample) |
| IL (1) | IL257608B (enExample) |
| MX (1) | MX2018002340A (enExample) |
| PL (1) | PL3341016T3 (enExample) |
| RS (1) | RS64449B1 (enExample) |
| SM (1) | SMT202300220T1 (enExample) |
| TW (1) | TWI715617B (enExample) |
| WO (1) | WO2017035181A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE045482T2 (hu) * | 2005-06-27 | 2019-12-30 | Glaxosmithkline Biologicals Sa | Immunogén készítmény |
| HUE038915T2 (hu) | 2013-01-17 | 2018-12-28 | Arsanis Biosciences Gmbh | MDR E. colira fajlagos antitest |
| NZ723328A (en) | 2014-02-24 | 2018-01-26 | Glycovaxyn Ag | Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| TW201946650A (zh) | 2018-03-12 | 2019-12-16 | 美商詹森藥物公司 | 針對腹內感染之疫苗 |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CR20210522A (es) | 2019-03-18 | 2021-12-17 | Janssen Pharmaceuticals Inc | Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos |
| IL286467B2 (en) | 2019-03-18 | 2026-02-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them |
| MY209568A (en) | 2020-01-16 | 2025-07-22 | Janssen Pharmaceuticals Inc | Fimh mutant, compositions therewith and use thereof |
| KR20220143910A (ko) * | 2020-02-23 | 2022-10-25 | 화이자 인코포레이티드 | 에스케리키아 콜라이 조성물 및 그의 방법 |
| ES2984813T3 (es) | 2020-04-28 | 2024-10-31 | Janssen Pharmaceuticals Inc | Método para la identificación y la cuantificación de polisacáridos en composiciones de glicoconjugados complejas |
| US20230226175A1 (en) | 2020-06-25 | 2023-07-20 | Glaxosmithkline Biologicals Sa | Modified exotoxin a proteins |
| PE20231385A1 (es) | 2020-09-17 | 2023-09-12 | Janssen Pharmaceuticals Inc | Composiciones de vacunas multivalentes y usos de las mismas |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| IL301880A (en) | 2020-11-30 | 2023-06-01 | Janssen Pharmaceuticals Inc | Analytical method for glycoconjugation using a capillary-based immunoassay system |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| CN116888140A (zh) | 2021-01-12 | 2023-10-13 | 杨森制药公司 | FimH突变体、其组合物及其用途 |
| US20220236283A1 (en) * | 2021-01-28 | 2022-07-28 | Janssen Pharmaceuticals, Inc. | Method for identification and quantification of polysaccharides in complex glycoconjugate compositions |
| WO2022178020A1 (en) | 2021-02-16 | 2022-08-25 | Duke University | Vaccine compositions and methods for the treatment and prevention of urinary tract infections |
| MX2023011697A (es) | 2021-04-01 | 2023-10-19 | Janssen Pharmaceuticals Inc | Produccion de bioconjugados o18 de e. coli. |
| KR20240005684A (ko) | 2021-04-08 | 2024-01-12 | 얀센 파마슈티칼즈, 인코포레이티드 | 바이오컨쥬게이트 생산 방법 |
| AR131046A1 (es) * | 2022-11-15 | 2025-02-12 | Janssen Pharmaceuticals Inc | Composiciones de vacunas multivalentes y sus usos |
| EP4478050A1 (en) | 2023-06-12 | 2024-12-18 | Janssen Pharmaceuticals, Inc. | Method for quantifying bound acetate in glycoconjugates |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
| CN118286407B (zh) * | 2024-04-08 | 2025-04-01 | 江西省农业科学院畜牧兽医研究所 | 一种禽大肠杆菌病三价灭活疫苗及其制备方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422653D0 (en) | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| AUPM399594A0 (en) | 1994-02-21 | 1994-03-17 | Csl Limited | Antigenic preparation for treatment or prevention of helicobacter infection |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| AU2001253568A1 (en) | 2000-04-18 | 2001-10-30 | Dan C. Deborde | Lipopolysaccharide-conjugate vaccine for sepsis treatment |
| RU2189253C1 (ru) | 2001-04-09 | 2002-09-20 | Государственный научный центр прикладной микробиологии | Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| DK1481057T3 (da) | 2002-03-07 | 2006-05-15 | Eidgenoess Tech Hochschule | System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| AU2005229434B2 (en) | 2004-03-30 | 2010-09-30 | Nsgene A/S | Therapeutic use of a growth factor, NsG33 |
| EP1747262B1 (en) * | 2004-05-14 | 2012-09-26 | National Research Council Of Canada | Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates |
| ES2535084T3 (es) | 2005-05-11 | 2015-05-05 | Eth Zurich | Proteínas N-glicosiladas recombinantes procedentes de células procariotas |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| JP4791866B2 (ja) | 2006-03-24 | 2011-10-12 | 国立大学法人秋田大学 | 下痢原性大腸菌感染症の判別に用いられる固相等 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2009036379A2 (en) | 2007-09-14 | 2009-03-19 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| CN102037004A (zh) | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
| SI2257307T1 (sl) * | 2008-02-20 | 2018-09-28 | Glaxosmithkline Biologicals S.A. | Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic |
| MX2011011376A (es) | 2009-04-27 | 2012-04-20 | Immuron Ltd | Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico. |
| NO2501406T3 (enExample) | 2009-11-19 | 2018-05-19 | ||
| MX381912B (es) | 2010-07-16 | 2025-03-13 | Adimab Llc | Colecciones de anticuerpos. |
| US20130273098A1 (en) | 2010-12-10 | 2013-10-17 | Jeffrey T. Blue | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
| CA2847621A1 (en) | 2011-09-06 | 2013-03-14 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
| US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
| WO2014037585A1 (en) | 2012-09-10 | 2014-03-13 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
| KR20150068998A (ko) | 2012-10-12 | 2015-06-22 | 글리코박신 아게 | 숙주 세포 변형 방법 |
| CA2896157A1 (en) | 2012-12-27 | 2014-07-03 | Glycovaxyn Ag | Methods and compositions relating to crm197 |
| HUE038915T2 (hu) | 2013-01-17 | 2018-12-28 | Arsanis Biosciences Gmbh | MDR E. colira fajlagos antitest |
| BR112016007727A8 (pt) | 2013-10-11 | 2018-01-30 | Glycovaxyn Ag | célula hospedeira, e, método para produzir uma proteína n-glicosilada. |
| KR102301188B1 (ko) | 2014-02-06 | 2021-09-13 | 엑스4 파마슈티컬스 (오스트리아) 게엠베하 | 이. 콜라이 특이성 항체 서열 |
| NZ723328A (en) | 2014-02-24 | 2018-01-26 | Glycovaxyn Ag | Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture |
| SI3240895T1 (sl) | 2014-12-30 | 2022-04-29 | Glaxosmithkline Biologicals S.A. | Sestavki in postopki za glikozilacijo proteinov |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| AR109621A1 (es) * | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| IL286467B2 (en) | 2019-03-18 | 2026-02-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them |
| CR20210522A (es) | 2019-03-18 | 2021-12-17 | Janssen Pharmaceuticals Inc | Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos |
| FR3098334B1 (fr) | 2019-07-05 | 2021-07-23 | Airbus Operations Sas | Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef |
-
2016
- 2016-08-23 TW TW105126945A patent/TWI715617B/zh active
- 2016-08-24 JP JP2018510886A patent/JP6872532B2/ja active Active
- 2016-08-24 HU HUE16760616A patent/HUE063961T2/hu unknown
- 2016-08-24 MX MX2018002340A patent/MX2018002340A/es unknown
- 2016-08-24 EP EP23176994.4A patent/EP4245320A3/en active Pending
- 2016-08-24 EP EP16760616.9A patent/EP3341016B9/en active Active
- 2016-08-24 RS RS20230664A patent/RS64449B1/sr unknown
- 2016-08-24 AU AU2016312422A patent/AU2016312422B2/en active Active
- 2016-08-24 PL PL16760616.9T patent/PL3341016T3/pl unknown
- 2016-08-24 ES ES16760616T patent/ES2951408T3/es active Active
- 2016-08-24 US US15/754,867 patent/US10583185B2/en active Active
- 2016-08-24 CN CN201680062232.7A patent/CN108430500B/zh active Active
- 2016-08-24 EA EA201890400A patent/EA037500B1/ru unknown
- 2016-08-24 HR HRP20230947TT patent/HRP20230947T1/hr unknown
- 2016-08-24 SM SM20230220T patent/SMT202300220T1/it unknown
- 2016-08-24 BR BR112018003469A patent/BR112018003469A2/pt not_active Application Discontinuation
- 2016-08-24 WO PCT/US2016/048278 patent/WO2017035181A1/en not_active Ceased
- 2016-08-24 KR KR1020187007898A patent/KR102735147B1/ko active Active
-
2018
- 2018-02-19 IL IL257608A patent/IL257608B/en unknown
-
2020
- 2020-02-04 US US16/781,526 patent/US11484582B2/en active Active
-
2022
- 2022-09-23 US US17/934,781 patent/US12076385B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12076385B2 (en) | Methods and compositions for immune protection against extra-intestinal pathogenic E. coli | |
| JP2018525423A5 (enExample) | ||
| Zhang et al. | Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice | |
| Rodrigues et al. | Development and evaluation of a new recombinant protein vaccine (YidR) against Klebsiella pneumoniae infection | |
| Chaisri et al. | Localization of Shiga toxins of enterohaemorrhagic Escherichia coli in kidneys of paediatric and geriatric patients with fatal haemolytic uraemic syndrome | |
| PE20231385A1 (es) | Composiciones de vacunas multivalentes y usos de las mismas | |
| Taheri et al. | Protective effects of egg yolk immunoglobulins (IgYs) developed against recombinant immunogens CtxB, OmpW and TcpA on infant mice infected with Vibrio cholerae | |
| Jiang et al. | Live Streptococcus suis type 5 strain XS045 provides cross-protection against infection by strains of types 2 and 9 | |
| Klipstein et al. | Immunological interrelationships between cholera toxin and the heat-labile and heat-stable enterotoxins of coliform bacteria | |
| Shaughnessy et al. | An optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae | |
| Behrouz et al. | Cloning, expression, and purification of Pseudomonas aeruginosa flagellin, and characterization of the elicited anti-flagellin antibody | |
| CN106220737B (zh) | 融合蛋白及其在治疗艰难梭菌相关疾病中的应用 | |
| Mansouri et al. | Enhanced immunoprotection against Acinetobacter baumannii infection: Synergistic effects of Bap and BauA in a murine model | |
| Waddell et al. | Sodium deoxycholate facilitates systemic absorption of verotoxin 2e from pig intestine | |
| Laura et al. | E. coli alpha hemolysin and properties | |
| NZ739963B2 (en) | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli | |
| US10829542B2 (en) | Methods for affecting Salmonella infections | |
| CA2995873C (en) | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli | |
| JP6578546B2 (ja) | Ｌｔ阻害４価ペプチドおよびｅｔｅｃ感染症治療薬 | |
| Gandhimathi et al. | Applications of IgY in Human Medicine 16 | |
| HK40101369A (en) | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli | |
| US20060281684A1 (en) | Polymyxin B analogs for LPS detoxification | |
| Lithgow et al. | P1. 29 Attachment of the syphilis spirochete, treponema pallidum, to the vascular endothelium | |
| Mcnichol | Identification of the Regions of Cytotoxic Necrotizing Factor Type 1 Responsible for Receptor Binding and Enzymatic Activity | |
| Arun | STUDIES ON IMMUNOGENICITY AND PROTECTIVE EFFICACY OF DIFFERENT RECOMBINANT PROTEINS OF PSEUDOMONAS AERUGINOSA |